News

Home>News
Apr 25 2023

Halberd Corporation 1Q23 CEO Letter

By |2023-04-24T20:53:26-04:00April 25th, 2023|Investor News, News, Press Releases, Update Letter|0 Comments

Jackson Center, PA, April 25, 2023 -- Halberd Corporation (OTC: HALB). The first quarter 2023 continued this extraordinarily groundbreaking path, packed with new accomplishments. 1st QUARTER 2023 ACHIEVEMENTS Halberd researchers received from the CDC (Centers for Disease Control and Prevention) an array of antibiotic-resistant bacteria (ARB) and deadly fungi for testing. Halberd’s laser eradication application ...

Apr 20 2023

$HALB CEO, CTO and #YSU’s Dr. Sturrus Discuss CDC, Research Discoveries etc., on “The Street Reports Podcasts” Listen Now!

By |2023-04-19T17:57:22-04:00April 20th, 2023|Featured, Investor News, News, Uncategorized|0 Comments

Jackson Center, PA, April 20, 2023 – Halberd Corporation’s (OTC-PINK: "HALB") President & CEO, William A. Hartman, its Chief Technical Officer, Dr. Mitchell S. Felder, and Youngstown State University (YSU) Professor/lead researcher, Dr. Wm. Gregg Sturrus were interviewed on “The Street Reports” to discuss the company’s latest research discoveries and progress on eradicating CDC (Centers for ...

Apr 17 2023

ICYMI: Halberd and YSU Interviewed on CBS Affiliate WKBN 5pm News as Research Advances

By |2023-04-16T18:54:51-04:00April 17th, 2023|Investor News, News, Press Releases|0 Comments

Jackson Center, PA, April 17, 2023 – Halberd Corporation’s (OTC PINK:HALB) successful patent protected research being conducted at Youngstown State University (YSU) on antibiotic resistant bacteria and deadly Candida auris was recently featured in a news segment on Youngstown, OH CBS News affiliate television station, WKBN. Professors and student scholar lab assistants are conducting this ...

Apr 11 2023

Halberd Begins Preclinical Testing at Mississippi State University (MSU)

By |2023-04-11T08:01:10-04:00April 11th, 2023|Featured, Investor News, News|0 Comments

Jackson Center, PA April 11, 2023 – Halberd Corporation (OTC-PINK: "HALB”) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify ...

Apr 3 2023

Halberd’s Successful Meeting with CDC Leads to Expanded Testing of Antibiotic Resistant Pathogens

By |2023-04-03T05:07:20-04:00April 3rd, 2023|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, April 3, 2023 – Halberd Corporation (OTC PINK:HALB) on March 29th met with five representatives from the Centers for Disease Control and Prevention (CDC). The CDC discussed Halberd’s incredible success eradicating multiple strains of antibiotic resistant (AR) E. coli bacteria and deadly Candida auris samples previously provided by the CDC. Halberd participants ...

Mar 30 2023

Halberd and Mississippi State University (MSU) Sign Agreement to Conduct Pre-Clinical Model Tests of Nasal Spray to Block Negative Effects of Head Trauma

By |2023-03-29T19:43:38-04:00March 30th, 2023|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA March 30, 2023 – Halberd Corporation (OTC-PINK: "HALB”) and Mississippi State University (MSU) signed an agreement outlining the testing in pre-clinical models which will be conducted at MSU.  The testing will focus on Halberd’s patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining ...

Mar 21 2023

Halberd Eradicates All Strains of Antibiotic Resistant E. Coli Provided by the CDC at Youngstown State University

By |2023-03-21T18:30:21-04:00March 21st, 2023|Investor News, Medical, News, Press Releases, Uncategorized|0 Comments

Jackson Center, PA, March 21, 2023 – Halberd Corporation (OTC PINK:HALB), leading up to the scheduled meeting with the Centers for Disease Control (CDC) on March 29, 2023, is pleased to report it has successfully eradicated all of the strains of antibiotic resistant E. coli samples previously provided by the CDC.  Using Halberd’s patented extracorporeal ...

Feb 21 2023

Halberd Demonstrates Simultaneous Eradication of Multiple Strains of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-21T05:34:56-05:00February 21st, 2023|Featured, Investor News, Medical, News, Press Releases|0 Comments

Killed 99.5% of a mixture of four strains of E. coli bacteria in buffer solution in-vitro Jackson Center, PA, February 21, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated the ability to simultaneously eradicate multiple strains of antibiotic resistant E. coli provided by the CDC in under ten minutes.  Halberd’s patented extracorporeal process and patent-pending ...

Feb 13 2023

Halberd Corporation Announces Breakthrough in Candida auris Treatment

By |2023-02-12T19:53:01-05:00February 13th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Halberd Demonstrates Eradication of Candida Auris Fungus in as little as five minutes. Jackson Center, PA, February 13, 2023 – Halberd Corporation (OTC PINK:HALB) a leading provider of innovative healthcare solutions, is proud to announce a major breakthrough in the development of a treatment for Candida auris infections. Candida auris is one of the antibiotic ...

Feb 8 2023

Halberd Demonstrates Eradication of CDC Provided Antibiotic Resistant Bacteria

By |2023-02-08T04:58:45-05:00February 8th, 2023|Investor News, Medical, News, Press Releases|0 Comments

Youngstown State University (YSU) Professors and Student Scholars Successfully Conduct Research Testing Jackson Center, PA, February 8, 2023 – Halberd Corporation (OTC PINK:HALB) has demonstrated its patent-pending extracorporeal laser eradication process is capable of eliminating antibiotic resistant strains of CDC provided bacteria samples.  Previously, Halberd demonstrated success in eliminating Escherichia coli and other Gram-Negative bacteria ...

Go to Top